Researchers Shared Asthma Exacerbation Data in September
New study data presented at the European Respiratory Society Congress 2026 highlights key drivers of persistent asthma.
Updated on Oct. 6, 2026 in Asthma
Live Poll
Should clinicians prioritize inflammatory phenotyping before escalating chronic illness treatment?
Experts shared findings on asthma exacerbations in September 2026, advising clinicians to analyze patient inflammatory phenotypes before adjusting treatment. The research focused on identifying specific biological triggers for patients failing to respond to current biologic therapies.
Why it matters
Understanding the specific drivers of residual asthma symptoms helps clinicians avoid unnecessary treatment escalation. Proper biomarker profiling ensures that patients receive the most effective intervention based on their unique inflammatory profile.
The ORACLE2 study analyzed over 7000 patients and found that a BMI exceeding 25 kg/m² correlates with higher exacerbation risk. Separately, the BenRex study identified airway neutrophilia in 55% of cases and Haemophilus influenzae in 18.2% of samples.
The players
European Respiratory Society
This is a leading international medical organization that promotes lung health and conducts large-scale professional congresses.
ORACLE2 study researchers
These investigators analyze large-scale health data to determine how physiological factors like BMI impact the severity of chronic respiratory conditions.
The details
Researchers utilized blood, nasal, and sputum samples to identify the underlying inflammatory phenotypes of patients experiencing exacerbations despite receiving biologics like mepolizumab or tezepelumab. By pinpointing these biological indicators, medical teams aim to provide more targeted care for patients with moderate to severe asthma.
Timeline
The European Respiratory Society Congress 2026 took place in September 2026.
The TezEx trial data was accessed on October 6, 2026.
The Big Picture
The presentation of asthma data at the European Respiratory Society Congress tracks global shifts in respiratory precision medicine. These findings extend the body of clinical evidence typically disseminated through this annual meeting.
Patients with severe asthma may benefit from more personalized treatment plans that account for specific inflammatory biomarkers. Clinicians may now request more frequent blood or sputum analysis to distinguish between neutrophilic and eosinophilic exacerbation triggers.
The takeaway
Asthma management is moving toward a more nuanced approach that prioritizes biological testing over one-size-fits-all medication adjustments. Patients should discuss the results of their most recent biomarker tests with their specialist to ensure their current treatment plan remains appropriate.
Further reading
For more information on chronic lung conditions, visit our Asthma section.
More information
View the TezEx study information page for full study details.
Source note: This article includes information reported by Hcplive.
Live Poll
Should clinicians prioritize inflammatory phenotyping before escalating chronic illness treatment?
